Business Description
CERo Therapeutics Holdings Inc
NAICS : 541713
SIC : 2833
ISIN : US71902K4022
Total Employee Number:
8Description
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.43 | |||||
Equity-to-Asset | -4.2 | |||||
Debt-to-Equity | -0.07 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 87.4 | |||||
3-Year EPS without NRI Growth Rate | 79.5 | |||||
3-Year FCF Growth Rate | 88.5 | |||||
3-Year Book Growth Rate | 95.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 67 | |||||
9-Day RSI | 60.85 | |||||
14-Day RSI | 53.87 | |||||
3-1 Month Momentum % | -65.63 | |||||
6-1 Month Momentum % | -74.42 | |||||
12-1 Month Momentum % | -99.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.14 | |||||
Quick Ratio | 0.14 | |||||
Cash Ratio | 0.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1516.1 | |||||
Shareholder Yield % | 129.72 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -432.15 | |||||
ROIC % | -687.16 | |||||
3-Year ROIIC % | 232.05 | |||||
ROC (Joel Greenblatt) % | -1689.83 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -0.38 | |||||
EV-to-Forward-EBIT | -0.46 | |||||
EV-to-EBITDA | -0.4 | |||||
EV-to-FCF | -0.52 | |||||
Earnings Yield (Greenblatt) % | -263.16 | |||||
FCF Yield % | -2660.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CERO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CERo Therapeutics Holdings Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -73.306 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 101.63 | ||
| 14-Day RSI | 53.87 | ||
| 14-Day ATR ($) | 0.00395 | ||
| 20-Day SMA ($) | 0.011316 | ||
| 12-1 Month Momentum % | -99.87 | ||
| 52-Week Range ($) | 0.007 - 8.9 | ||
| Shares Outstanding (Mil) | 45.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CERo Therapeutics Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CERo Therapeutics Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.05:1 Stock Split | 2025-06-13 | 7.87 (+6.64%) | ||
| 0.01:1 Stock Split | 2025-01-08 | 104.60 (-9.83%) |
Show
Entries
CERo Therapeutics Holdings Inc Frequently Asked Questions
What is CERo Therapeutics Holdings Inc(CERO)'s stock price today?
The current price of CERO is $0.01. The 52 week high of CERO is $8.90 and 52 week low is $0.01.
When is next earnings date of CERo Therapeutics Holdings Inc(CERO)?
The next earnings date of CERo Therapeutics Holdings Inc(CERO) is .
Does CERo Therapeutics Holdings Inc(CERO) pay dividends? If so, how much?
CERo Therapeutics Holdings Inc(CERO) does not pay dividend.
Guru Commentaries on OTCPK:CERO
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients | 2024-03-07 |
Articles on CERo Therapeutics Holdings Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers